This site is intended for healthcare professionals
CAT_Thrombosis
Venous Thromboembolism (VTE) Learning Zone

Cancer-associated thrombosis (CAT)

Read time: 50 mins
Last updated:4th May 2023
Published:25th Feb 2022

Take an in-depth look at thrombosis in cancer (cancer-associated thrombosis, CAT), the second leading cause of death in patients with malignant tumours.

  • Join Professor Agnelli from the University of Perugia to explore the prevalence of CAT and how to identify those at risk
  • Explore options for prevention of CAT and for initial, short-term and long-term treatment
  • Learn about the key evidence behind inclusion of direct-acting oral anticoagulants (DOACs) as options for prevention and treatment of CAT in 2021 guidelines

About cancer-associated thrombosis

Cancer-associated thrombosis (CAT) collectively refers to thrombotic events in patients with cancer, and most commonly includes types of venous thromboembolism (VTE) such as deep vein thrombosis (DVT) and pulmonary embolism (PE)1. It also includes less common types of VTE, such as visceral or splanchnic vein thrombosis, and arterial occlusion with stroke and symptoms of angina1.

Prevalence and impact of cancer-associated thrombosis

Professor Agnelli describes the prevalence of CAT, and the challenges of treating patients with the condition.

What are the challenges of treating CAT?
3

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Risk assessment for cancer-associated thrombosis

Professor Agnelli outlines the key risk factors for cancer-associated thrombosis (CAT), and how clinicians can stratify patients based on their risk of thrombosis, to help inform treatment options.

What are the risk factors for CAT and what risk stratification tools are available?
How can physicians stratify patients based on risk?
1

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Direct-acting oral anticoagulants in cancer-associated thrombosis

Professor Agnelli discusses the evidence for direct-acting oral anticoagulants (DOACs) in the treatment of venous thromboembolism (VTE) in patients with cancer, and whether DOACS may help to overcome some challenges in managing CAT.

Is there sufficient data to support use of DOACs for treatment of CAT
Could DOACs overcome issues in management of CAT
2

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

References

  1. Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: An overview. Clinical Medicine Insights: Oncology. 2014;8:129-137.
  2. Fernandes CJ, Morinaga LTK, Alves JL, Castro MA, Calderaro D, Jardim CVP, et al. Cancer-associated thrombosis: The when, how and why. European Respiratory Review. 2019;28(151).
  3. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–974.
  4. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
  5. Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G. Update on guidelines for the management of cancer-associated thrombosis. Oncologist. 2021;26(1):e24-e40.
  6. Oppelt P, Betbadal A, Nayak L. Approach to chemotherapy-associated thrombosis. Vascular Medicine (United Kingdom). 2015;20(2):153-161.
  7. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, et al. Risk of venous thromboembolism in patients with cancer treated with cisplatin: A systematic review and meta-analysis. Journal of Clinical Oncology. 2012;30(35):4416-4426.
  8. Zahir MN, Shaikh Q, Shabbir-Moosajee M, Jabbar AA. Incidence of venous thromboembolism in cancer patients treated with cisplatin based chemotherapy - a cohort study. BMC Cancer. 2017;17(1).
  9. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis. Journal of Clinical Oncology. 2011;29(25):3466-3473.
  10. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Euro Heart J. 2020;41(4):543–603.
  11. Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. European Journal of Vascular and Endovascular Surgery. 2021;61(1):9-82.
  12. Mulder FI, Candeloro M, Kamphuisen PW, Di Nisio M, Bossuyt PM, Guman N, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis. Haematologica. 2019;104(6):1277-1287.
  13. Falanga A, Schieppati F, Russo L. Pathophysiology 1. mechanisms of thrombosis in cancer patients. Cancer Treatment and Research. 179: Springer International Publishing; 2019. p. 11-36.
  14. this reference needs to be recategorised
  15. National Comprehesive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: cancer-assoicated venous thromboembolic disease. https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf. Accessed March 2023.
  16. Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: A real‐world analysis. The Oncologist. 2013;18(12):1321-1329.
  17. Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thrombosis Research. 2018;164:S112-S118.
  18. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute. 2006;98:708-714.
  19. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974.
  20. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–347.
  21. Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Annals of Oncology. 2023.
  22. Key NS, Chb MB, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. Journal of Clinical Oncology. 2019;38:496-520.
  23. Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738.
  24. Wang TF, Zwicker JI, Ay C, Pabinger I, Falanga A, Antic D, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2019;17(10):1772-1778.
  25. Gervaso L, Dave H, Khorana AA. Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology. 2021;3(2):173-190.
  26. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017-2023.
  27. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine. 2018;378(7):615-624.
  28. Kraaijpoel N, Di Nisio M, Mulder FI, Van Es N, Beyer-Westendorf J, Carrier M, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the Hokusai VTE cancer study. Thrombosis and Haemostasis. 2018;118(8):1439-1449.
  29. Angelini DE, Attia D, Wei WMS, Wilks ML, Tripp B, D'Andrea C, et al. Bleeding outcomes of gastrointestinal cancer patients treated with direct oral anticoagulants vs. low molecular weight heparin. 2020.
  30. Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: Results from the Caravaggio study. Thrombosis and Haemostasis. 2021;121(5):616-624.
  31. Ladha D, Mallick R, Wang TF, Caiano L, Wells PS, Carrier M. Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. Thrombosis Research. 2021;202:151-154.
  32. Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, Carrier M, Duggal A, et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thrombosis Research. 2020;185:13-19.
  33. Chen J, Lv M, Wu S, Jiang S, Xu W, Qian J, et al. Severe bleeding risks of direct oral anticoagulants in the prevention and treatment of venous thromboembolism: A network meta-analysis of randomised controlled trials. Journal of Vascular Surgery. 2022;75(4):1494.
  34. Chen X, Wang L, Li H, Huang W, Zhao L, Guo W. Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: An updated traditional and Bayesian network meta-analysis. Front Pharmacol. 2022;13:1049283.
  35. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine. 2020;382(17):1599-1607.
  36. Souverein PC, van den Ham HA, Huerta C, Merino EM, Montero D, León-Muñoz LM, et al. Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. British Journal of Clinical Pharmacology. 2021;87(3):988-1000.
  37. Iwai C, Jo T, Konishi T, Kumazawa R, Matsui H, Fushimi K, et al. Comparative safety and effectiveness of direct oral anticoagulants and warfarin during chemotherapy in cancer patients with venous thromboembolism aged 75 years or older: A nationwide inpatient database study. Gerontology. 2022.
  38. Eliquis® (apixaban) full prescribing information. Last revised April 2021: Administration USFaD; 2021.
  39. Xarelto® (rivaroxaban) full prescribing information. Last updated January 2021: Administration USFD; 2021.
  40. Apixaban EPAR product information. Last revised July 2021: Accord Healthcare SLU; 2021.
  41. Rivaroxaban EPAR product information. Last updated December 2021: Accord Healthcare SLU; 2021.
  42. Pradaxa® (dabigatran) full prescribing information. Last updated April 2021: Food US, Drug A; 2021.
  43. Edoxaban tosilate EPAR product information. Last updated January 2022: Daiichi Sankyo Europe Gm BH; 2020.
  44. Dabigatran etexilate mesilate EPAR product information. Last updated January 2022: Boehringer Ingelheim International Gmb H; 2020.
  45. Savaysa® (edoxaban) full prescribing information. Last updated April 2021: Administration USFD; 2021.
  46. Bevyxxa® (betrixaban) full prescribing information. Last revised June 2017: Administration USFD; 2017.
  47. European Medicines Agency. Dexxience® (betrixaban). 2018. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/dexxience.
  48. Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. Journal of Thrombosis and Haemostasis. 2012;10(5):807-814.
  49. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to prevent venous thromboembolism in patients with cancer. New England Journal of Medicine. 2019;380(8):711-719.
  50. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. New England Journal of Medicine. 2019;380(8):720-728.
  51. Longo de Oliveira ALM, de Oliveira Pereira RF, Agati LB, Ribeiro CM, Kawamura Suguiura GY, Cioni CH, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after major gynecological cancer surgery: the VALERIA trial. Clin Appl Thromb Hemost. 2022;28:10760296221132556.
  52. Di Nisio M, van Es N, Carrier M, Wang TF, Garcia D, Segers A, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis. 2019;17(11):1866-1874.
  53. McBane RD, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. Journal of Thrombosis and Haemostasis. 2020;18(2):411-421.
  54. Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mahé I, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: A randomized trial. Chest. 2022;161(3):781-790.

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Welcome: